ストックスクリーナーアプリを入手
60.00
3.34%
1.94
プレマーケット:
58.52
-1.48
-2.47%
前日終値:
$58.06
開ける：
$58.82
24時間の取引高:
1.17M
Relative Volume:
0.69
時価総額：
$5.76B
収益：
$3.51M
当期純損益:
$-581.60M
株価収益率:
-9.2102
EPS:
-6.5145
ネットキャッシュフロー:
$-345.93M
1週間 パフォーマンス:
+8.70%
1か月 パフォーマンス:
+19.59%
6か月 パフォーマンス:
+13.77%
1年 パフォーマンス:
+38.09%
1日の値動き範囲:
$57.75
$60.60
1週間の範囲:
$53.75
$61.76
52週間の値動き範囲:
$30.04
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Compare CRSP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
60.00 | 5.57B | 3.51M | -581.60M | -345.93M | -6.5145 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | 開始されました | JP Morgan | Overweight |
| 2025-02-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-02-12 | アップグレード | TD Cowen | Sell → Hold |
| 2025-02-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-08-02 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-28 | 再開されました | Guggenheim | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-11 | ダウングレード | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 開始されました | Mizuho | Buy |
| 2023-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-04-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2023-03-07 | 開始されました | Robert W. Baird | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-08-09 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | アップグレード | Citigroup | Sell → Neutral |
| 2021-04-21 | アップグレード | Jefferies | Hold → Buy |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2020-12-10 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-10 | 繰り返されました | Needham | Buy |
| 2020-12-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-07-28 | 繰り返されました | Needham | Buy |
| 2020-07-14 | 開始されました | SunTrust | Buy |
| 2020-06-15 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-19 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 開始されました | Jefferies | Buy |
| 2019-07-26 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-10 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-14 | 開始されました | William Blair | Mkt Perform |
| 2019-01-28 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-22 | ダウングレード | Citigroup | Neutral → Sell |
すべてを表示
Crispr Therapeutics Ag (CRSP) 最新ニュース
Amova Asset Management Americas Inc. Decreases Position in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG $CRSP is ARK Investment Management LLC's 8th Largest Position - MarketBeat
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of - The Motley Fool
CRISPR Therapeutics AG $CRSP Position Raised by Vanguard Group Inc. - MarketBeat
Contrarius Group Holdings Ltd Sells 104,604 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRSP Stock Price and Chart — NASDAQ:CRSP - TradingView
Here’s What You Should Understand Besides the Reason CRISPR Therapeutics AG (CRSP) is Gaining Attention - Bitget
Is CRISPR Therapeutics Stock Too Risky to Buy Right Now? - The Motley Fool
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - Yahoo Finance
TD Asset Management Inc Sells 53,800 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Rafferty Asset Management LLC Has $10 Million Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Vertex Interest Renews CRISPR Therapeutics Takeover Talk And Investor Questions - Sahm
HighTower Advisors LLC Reduces Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
FDA Draft Guidance Puts CRISPR Therapeutics Gene Editing Outlook In Focus - Sahm
Crispr Therapeutics AG Surges on Takeover Buzz and Hype - TipRanks
JPMorgan Chase & Co. Buys 294,222 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics Takeover Chatter With Vertex Puts Investor Tradeoffs In Focus - Sahm
Here’s What Analysts Are Saying About CRISPR Therapeutics AG (CRSP) - Yahoo Finance
CRISPR Therapeutics Hits Day High with 11.85% Surge in Stock Price - Markets Mojo
CRISPR Therapeutics Shares Surge on Strong Earnings and Pipeline Growth - Intellectia AI
CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch - TechStock²
Crispr Therapeutics (CRSP) Shares Surge on Takeover Speculation - GuruFocus
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 11.2%Still a Buy? - MarketBeat
Why Is CRISPR Therapeutics Stock Surging Thursday? - Benzinga
Crispr Therapeutics (CRSP) Rumored in M&A Discussions Once More - GuruFocus
Rumor Mill Sends Crispr Therapeutics Shares Climbing Again - TipRanks
Assessing CRISPR Therapeutics (CRSP) Valuation After FDA Draft Guidance And Recent Weak Earnings - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Should You Buy Shares of CRISPR Therapeutics in February? - aol.com
CRISPR Therapeutics AG (CRSP) Stock Analysis: Unveiling A 57% Potential Upside - DirectorsTalk Interviews
CRISPR Therapeutics AG Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Versant Venture Management LLC Decreases Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
FDA's New Framework Could Benefit CRISPR Therapeutics (CRSP) - GuruFocus
(CRSP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
CRISPR Therapeutics gains after earnings as pipeline hope grows - MSN
Rare disease pharmas could benefit from FDA guidance to accelerate development - Seeking Alpha
Volume Report: Will CRISPR Therapeutics AG benefit from sector rotation2025 Technical Overview & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
O Neil Global Advisors Inc. Acquires Shares of 168,715 CRISPR Therapeutics AG $CRSP - MarketBeat
How FDA RMAT Status For Zugo-cel Amid Wider Losses At CRISPR Therapeutics (CRSP) Has Changed Its Investment Story - simplywall.st
Vestmark Advisory Solutions Inc. Has $15.49 Million Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel Sells $111,048.96 in Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $366,324.86 in Stock - MarketBeat
CRISPR Therapeutics (CRSP) CEO sells shares to cover RSU taxes - Stock Titan
Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off? - The Motley Fool
First Week of October 16th Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices - The Motley Fool
CRISPR Therapeutics (CRSP) legal chief reports RSU share vesting and tax sale - Stock Titan
What’s next for CRISPR Therapeutics AG stockJuly 2025 Setups & Verified Entry Point Detection - mfd.ru
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street - AOL.com
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows - sharewise.com
Crispr Therapeutics Ag (CRSP) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):